The Pharmaceutical Supply Chain Initiative (PSCI) has released a position paper on the use of Horseshoe Crabs in the pharmaceutical sector. The paper takes a progressive stance, noting the potential animal welfare and sustainability impacts of the use of Horseshoe Crab blood within the industry, and aims to encourage its member companies to minimize their use and seek out safe alternatives for their supply chains.
 
While this paper is not a membership requirement for the PSCI, it does outline the organization’s views on good practice as it continues its commitment to the protection of all endangered species. It is important the industry has a strategy for reducing its dependence on Horseshoe Crab-derived products, and the PSCI is committed to working with its members to facilitate their progress and report the position across the whole industry.

The full position paper is available to download below.